

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

DESIGNING AND EVALUATING PROVIDER RESULTS-BASED FINANCING FOR TUBERCULOSIS CARE IN GEORGIA: A REALIST EVALUATION PROTOCOL

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030257
Article Type:	Protocol
Date Submitted by the Author:	07-Mar-2019
Complete List of Authors:	Marchal, Bruno; Institute of Tropical Medicine, Department of Public Health Giralt , Ariadna; Institute of Tropical Medicine, Department of Public Health Sulaberidze, Lela; Curatio International Foundation Chikovani, Ivdity; Curatio International Foundation Abejirinde, Ibukun-Oluwa; Institute of Tropical Medicine, Department of Public Health
Keywords:	realist evaluation, research protocol, Georgia, results-based financing, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

DESIGNING AND EVALUATING PROVIDER RESULTS-BASED FINANCING FOR TUBERCULOSIS CARE IN GEORGIA: A REALIST EVALUATION PROTOCOL

Bruno Marchal ¹, Ariadna Nebot Giralt ¹, Lela Sulaberidze ², Ivdity Chikovani ², Ibukun-Oluwa
Omolade Abejirinde* ¹

¹ Institute of Tropical Medicine, Health Systems and Equity Unit, Department of Public
Health, Antwerp, Belgium

² Curatio International Foundation, Tbilisi, Georgia

33
34
35
36
37
38
39
40
41
42
43
44

Corresponding Author

Ibukun-Oluwa Omolade Abejirinde
Institute of Tropical Medicine, Department of Public Health,
Health Systems and Equity Unit,
Nationalestraat 155, Antwerp, Belgium
iabejirinde@itg.be

45
46
47
48
49

Keywords: realist evaluation, research protocol, Georgia, results-based financing, health
policy

50
51
52

Word Count

53
54
55
56
57
58
59
60

3804 (including tables)

Abstract

Introduction

In 2016, Georgian researchers and policymakers were developing a policy to improve the performance of the national tuberculosis (TB) control programme. The research programme “Designing and Evaluating Provider Results-Based Financing for Tuberculosis Care in Georgia: Understanding Costs, Mechanisms of Effect and Impact (Results4TB)” was initiated to inform the policy formulation phase, document the policy implementation and assess the effectiveness, cost-effectiveness and the processes of change. To achieve this, the research team intends to combine an impact evaluation, a cost-effectiveness study and a realist evaluation within an overarching theory-informed design. This protocol is the realist evaluation component of the programme.

Methods

A realist methodological approach will be adopted to guide the research design and evaluation. Realist evaluation answers the question of ‘what works in which conditions for whom?’ and starts with the development of an initial program theory (IPT). The IPT will feed into other phases of the realist research cycle (study design, data collection, data analysis and synthesis, and theory refinement). Data will be collected in a multiple embedded case study design (five intervention and three control sites) through document reviews, in-depth interviews, non-participant observations and context mapping at facility and national levels. Additional data from other research components (cost-effectiveness and impact evaluation) will aid data triangulation.

Discussion

This realist evaluation is part of a large theory-driven study that combines the impact evaluation of a policy trial, cost-effectiveness and realist evaluation studies in order to better integrate data collection and analysis and arrive at an integrated policy assessment.

Ethics and dissemination

The Institutional Review Boards of the National Centre for Disease Control and Public Health in Georgia (ref. IRB # 2018-019) and the Institute of Tropical Medicine, Antwerp (ref. IRB #- 1240/18) have granted ethical approval to the study.

Strengths and Limitations of this study

- This study uses an integrated theory-informed design for a combined impact, cost-effectiveness and process evaluation of a policy, thus addressing a currently debated methodological challenge
- Addressing a policy that is being developed, the study may be faced with unexpected turns in the policymaking and implementation phases.
- The realist evaluation cycle fosters a flexible and iterative structure for learning and reflection. For example, applying a realist approach led to the formulation of a more comprehensive and contextually relevant policy package.

Introduction

Under the national TB program in Georgia, Eastern Europe, Tuberculosis (TB) service is provided to patients free of charge. At outpatient level, services are provided at TB units by TB doctors and TB nurses. There are currently 68 TB units in the country: 58 semi-urban (located in district centers) and 10 urban TB units. Recently, semi-urban TB units were administratively integrated into district and regional level primary health care (PHC) centers, most of which are private. Therefore only a few TB units remain as separate public institutions, existing mainly in the capital and other major cities of the country (10 urban centers). TB service integration into PHC was part of a wider healthcare privatization process whereby although it was not profitable from a private sector perspective, the government (represented by the Ministry of Health through the National TB programme) and private sector providers agreed that the latter will provide TB services. This agreement was scheduled to expire in 2018.

While Georgia has made substantial progress in managing TB, challenges still remain. Data from 2017 indicate high rates of drug-resistant TB (DR-TB) in the Georgian population. The incidence was 11% in new TB patients and 30% in those previously treated.¹ In addition, there is suboptimal adherence to treatment among DR-TB patients in the country - every fourth DR-TB patient quits treatment prematurely. Poor coordination between PHC and TB units leading to fragmented TB care was assumed to contribute to poor treatment adherence and loss to follow-up (LFU).^{2,3}

During discussions on policy options to improve TB service provision in the country, results-based financing (RBF) of providers was proposed as a viable approach to motivate health care providers not only to continue

1
2
3 providing TB care, but also to improve treatment adherence in TB patients. Policymakers' willingness to pilot
4 the RBF model for TB initially materialized as a standard concept note to the Global Fund in 2015, where in
5 addition to other programmatic needs, the government requested financial support from the Global Fund
6 for technical assistance to design and implement the RBF model.
7
8
9

10
11 In 2016, Georgian and international researchers drafted a proposal aiming to support the Georgian
12 government in developing a policy to improve the performance of the National TB control programme and
13 generate evidence on the proposed policy. Consequently, a research programme "Designing and Evaluating
14 Provider Results-Based Financing for Tuberculosis Care in Georgia: Understanding Costs, Mechanisms of
15 Effect and Impact (Results4TB)" was initiated. Results4TB aims at informing the policy formulation phase,
16 documenting the implementation of the policy and assessing the effectiveness, cost-effectiveness and the
17 processes of change. To this end, the research team is combining an impact evaluation of the policy trial
18 with a cost-effectiveness study and a realist evaluation. Essentially, instead of developing three separate
19 sub-studies (impact, cost-effectiveness and process evaluation), each addressing a different set of research
20 questions, we will develop a theory-informed design that integrates all three components. Trial designs
21 often include implementation fidelity evaluations, process evaluations or context mapping,⁴ and there have
22 been calls for informing such evaluations with theory.^{5,6} The Results4TB study therefore goes a step further:
23 not just the process evaluation, but also the overall study design will be theory-informed.
24
25
26
27
28
29
30
31
32
33

34
35 This paper presents the protocol of the realist evaluation component, spelling out the objectives, research
36 questions, methods and ethical considerations. The trial has been registered with ID- ISRCTN14667607
37 (<http://www.isrctn.com/ISRCTN14667607>).
38
39
40
41

42 **Objectives**

43
44

45 The objective of the realist evaluation component is to identify the mechanisms of change and the
46 contextual factors that enhance or undermine the effectiveness of the provider results-based financing
47 policy, defined in terms of adherence and treatment outcomes.
48

49 The research questions include: (1) How is the performance based financing policy designed and by whom?;
50 2) How is the policy implemented in the study sites?; (3) How do the actors respond to the policy?; (4) What
51 are the contextual conditions needed for the policy to work?; (5) What are the underlying mechanisms that
52 explain how the policy contributes to a change in the practice of TB service providers and; (6) What are the
53 underlying mechanisms that explain how the policy contributes to a change in adherence?
54
55
56
57
58
59
60

Methods

The methodological approach

Pawson and Tilley (1997) developed the realist evaluation (RE) approach arguing that in order to be useful for decision makers, rather than merely addressing the question of 'does it work?', evaluations need to answer the question 'what works in which conditions for whom?'.⁷ In order to meet this need, realist evaluators therefore aim to identify the underlying generative mechanisms that explain how an intervention leads to its outcomes and in which context this occurs. Based on critical realism, RE considers that interventions work (or not) because actors respond to what is provided by the intervention (or not). The interaction between 'intervention' and 'actors' in specific 'contexts' therefore triggers mechanisms that lead to outcomes.

Realist evaluations start with an initial programme theory (IPT), on the basis of which the study design is based. The IPT explains how a programme is expected to generate outcomes by showing which mechanisms will be triggered among different groups of actors. It also identifies the necessary contextual conditions needed for the programme, in our case the Results4TB policy, to work. In other words, the IPT is a hypothesis that will be tested subsequently and iteratively through empirical studies. We structured our protocol following the steps of the realist cycle (Figure 1). The IPT, which has been formulated during stakeholder workshops, is briefly presented, following which additional components of the Results4TB realist evaluation are outlined as part of the research protocol.

Insert Figure 1

Step 1 - Developing the initial programme theory

Several data sources can be used to elicit the initial programme theory (Figure 2). These include programme documents including policy briefs, concept notes and logical frameworks. A second source is interviews with the designers, funders and/or implementers of the policy, combined with on-site observations. Third, past experience, findings of previous evaluations or research studies are reviewed. Finally, in some cases, exploratory research may be carried out.

Insert Figure 2

1
2
3
4
5
6
7 In this project, we combined existing literature reviews, workshops with policymakers and key stakeholders
8 involved in TB care. Furthermore, discussions within the research team were instrumental in refining and
9 constructing the initial programme theory. First, we built upon a review of the literature on adherence
10 carried out in the frame of the RELIVING study⁹ and on literature reviews carried out on performance-based
11 financing (PBF) and results-based financing (RBF), including one on PBF in low- and lower middle-income
12 countries.¹⁰

13
14
15
16 Second, we used the unique opportunity to involve both researchers and policymakers at the initial phase of
17 the project by organising two workshops. During the workshops, we used participatory and interactive
18 techniques to obtain a clearer insight on the proposed RBF policy and why the designers, implementers and
19 other stakeholders think the policy may or may not work. Workshop participants ranged from TB providers
20 to Ministry of Labour, Health and Social Affairs (MoLHSA) policymakers and representatives of the Global
21 Fund. We used cause mapping and concept mapping¹¹ to clarify how the participants understood the
22 problem (first workshop) and the potential policy options, discussing why one option would be more
23 effective than others (second workshop). The results were discussed by the research team members and
24 framed on the background of findings from the literature review.

25
26
27
28
29
30
31
32
33 The result of the above process was that we ended up with a more complex policy; it became evident that
34 the RBF for TB providers required expansion to address other challenges in the service delivery pathway.
35 Consequently, in response to the input from all stakeholders, the policy was defined as a package of
36 interventions, including

- 37 • Incentive payments (bonuses) to TB teams based on performance indicator (i.e. TB patient retained
38 on treatment);
 - 39 • Trainings for all members of a TB team (a TB doctor, a family doctor, a DOT nurse, a rural nurse) on
40 principles of integrated and patient-centred care, and on managing TB treatment side effects and
41 comorbidities (for family doctors and TB doctors);
 - 42 • New roles and responsibilities were ascribed to TB team members which were better aligned to the
43 scope of their professional competencies and in order to ensure integrated patient centred
44 approach for TB
 - 45 • Launch of new treatment and monitoring tools such as: facility managers guidelines on
46 implementing the policy, case management plan for patients, instruments for monitoring integrated
47 team performance, and instruments for verification of performance indicators and the incentive
48 scheme.
- 49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 This process led us to formulate the initial programme theory as follows (Fig. 3):
6

- 7 • Financial incentives will stimulate facility managers to (i) continue providing TB services, (ii) remit
8 incentives to TB providers within their facilities, and (iii) optimise their TB service activities (i.e.
9 *mechanism of organizational self-interest*), on the condition that incentives are considered to be
10 adequate and that sufficient monitoring and regulation systems are in place, in the absence of
11 which gaming and fraud could occur.
- 12 • Provider incentives will increase their extrinsic motivation (*mechanism*) if the staffing and working
13 conditions are adequate. Motivated and competent providers will provide better adherence
14 support to patients, if supervision, monitoring and regulation are adequate. If not, crowding out of
15 intrinsic motivation and gaming may occur.
- 16 • Training for providers (e.g. on side-effect of drugs, management of co-morbidities and patient-
17 centred care) will enhance their competence, which leads to higher self-efficacy. The latter,
18 combined with an increase in extrinsic motivation, contributes to behaviour change; enabling
19 patients to better adhere to the treatment.
- 20 • TB patients who are informed, motivated and supported by providers, and trained to develop the
21 needed skills, will initiate adherence if the social and cultural context is favourable (e.g. no
22 stigma), if the facility is accessible, acceptable and affordable, and if they consider the treatment
23 regime as acceptable.
- 24 • The integration of TB care will improve the continuum of care between general and specialised TB
25 services and thus facilitate the patient to correctly follow the treatment and care pathway
26 towards being cured.
- 27 • TB patients who experience positive effects, feel capable of managing their health condition (i.e.
28 mechanism of self-efficacy) and feel in control are more likely to maintain long-term adherence,
29 on condition that they consider the treatment regime as acceptable.
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Insert Figure 3

The formulated IPT will inform the study design and other phases of the realist cycle.

Step 2 - Study design

Given the research questions, we will adopt the multiple embedded case study design.¹² This design is often used in realist research in health⁸ and has the advantage that it is well adapted to dynamic concepts or interventions, such as a policy that is in the formulation or implementation phase.¹³

We define the case as the uptake and implementation, by facility managers and service providers, of the policy that will be introduced by the Ministry of Labour, Health and Social Affairs to improve TB drug adherence and treatment outcomes. The unit of analysis is the facility, which includes first-line and second-line health facilities in which TB care is provided. Within each facility, we focus on the influence of the policy on the interaction between managers, service providers and patients, and on TB service delivery. In realist evaluation, the selection of the study sites is purposive: ideally, sites should enable 'testing' of the initial programme theory in all its dimensions. The trial of the policy will be implemented in eight intervention and eight control facilities. For the realist evaluation, five intervention sites and three control sites will be chosen for data collection. Site selection will be purposive, based on the following criteria:

- Facilities of different types will be selected using ownership status (private-for-profit versus public) and organizational structure (large chain versus independent facility)
- Different subsets of service delivery modality- specialized TB services versus TB units integrated in primary health care centres.
- Location- semi-urban versus urban

Step 3 - Data collection

We will use a range of data collection techniques: document reviews, in-depth interviews, non-participant observations and a context mapping tool (Table 1). Additional data from other components of Results4TB will also be used to triangulate the data. Where possible data collection tools will be tested during a short pilot phase of the policy prior to full trial.

1.1 Document review

We will carry out a document review to collect data for research question 2 (i.e. how the policy is implemented in the study sites). The focus will be on finding evidence of the initiation and process of policy implementation at the facility. Facility reports, TB programme reports, data collected during policy implementation supervision and verification reports, and other relevant policy-related documents will be used. At study sites, documents related to monitoring of TB clinic activities, such as activity reports, will be

1
2
3 screened for information on implementation process and problems. Where possible, electronic versions will
4 be collected and entered in NVIVO software. If not, paper versions will be collected.
5
6

7 **1.2 In-depth interviews**

8
9 In order to address research questions 3- 6, we will carry out in-depth interviews with different actors in the
10 policy trail: facility managers, TB service providers, TB coordinators (who will conduct policy supervision and
11 verification role), TB patients and national-level respondents. Interview guides will be developed in
12 collaboration with the other project teams and with the local partner in Georgia. The guides will be first
13 translated into Georgian, piloted, and modified if needed. Table 1 presents the estimated number of
14 interviews per respondent type and level.
15
16
17
18

19 The following procedure will be used:

- 20
21 • All potential respondents will be invited to participate in the study by personal invitation using a
22 snowball approach. The researchers will invite facility managers, health care personnel and
23 national-level respondents. TB doctors will extend invitations to their patients, after receiving
24 training from the research team on recruitment and ethical procedures.
25
26
27
- 28 • Interested potential respondents will then receive and be guided through a participant
29 information sheet, explaining the study objectives and procedures.
30
31
- 32 • If participants are still interested to be interviewed, an interview will be arranged according to
33 their preferred time and location.
34
35
- 36 • At the start of the interview, the researchers will provide detailed information about the study
37 and the interview and answer any question.
38
39
- 40 • The informed consent form will be presented and explained by the researcher. Informed consent
41 will be sought at the start of the interview, as well as permission to record the interview.
42
43
- 44 • All recorded transcripts will be transcribed verbatim. A sample of interviews will be translated to
45 be used in an initial coding training workshop and will also allow for quality assessment by the
46 non-Georgian team members.
47
48
- 49 • Field-notes and memos will be entered in an electronic form.
50
51
- 52 • All transcripts and related memos will be entered in NVIVO for subsequent data analysis.
53

54 **1.3 Non-participant observation**

55 To collect information related to research questions 2 - 6, in addition to individual interviews, we will
56 conduct non-participant observations at TB clinics and observe the integrated TB team meetings, using
57 observation guides. Where possible, we will aim to observe the clinical encounter of each patient who has
58 agreed to be interviewed. Researchers will ask for written informed consent before conducting any
59 observation. Patients will be able to opt out, yet still participate in an interview.
60

1.4 Context mapping tool

In order to document the context of each facility and to identify contextual conditions for the intervention to work (research question 3), we will develop and use a facility context-mapping tool. This will be used to document key facility-related issues, including organisational structure, decision spaces, flow of funds and information, and the TB patient pathway. A national context mapping tool will be developed and used to identify the key stakeholders, track their engagement with the policy over time, identify key political and policy events and other events that may influence the policy implementation and or its outcomes.

For peer review only

Table 1 - Overview of data collection methods and targeted minimum numbers

Tools	Data source	Content	Minimum numbers	Time period	Responsible for data collection	Data collection technique
IDI-Providers	Service providers: TB doctor, TB nurse, family doctor, rural doctor, rural nurse	Personnel perspectives	40 (5 interviews/site)	One year after the intervention start	Researchers	Face to face interview (IDI guides)
IDI-Facility Managers	Facility manager, clinical manager	Managers perspectives	16 (2 interviews/site)	One year after the intervention start	Researchers	Face to face interview (IDI guides)
IDI-TB Coordinator	TB Coordinator	TB coordinators views	5	One year after the intervention start	Researchers	Face to face interview (IDI guides)
IDI-Patients	Patient	Patients perspectives	48 (3 DS + 3 DR patients per site)	One year after the intervention start	Researchers	Face to face interview (IDI guides)
IDI-National level	MoLHSA, National Center for Disease Control	National-level key actors' perspectives	5 interviews	15 months after the intervention start	Researchers	Face to face interview

respondents	(NCDC), the Global Fund, TB programme, Social Service Agency (SSA)					(IDI guides)
IDI-Network HQ	Top managers from each network	Network specific views	3 Interviews	One year after the intervention start	Researchers	Face to face interview (IDI guides)
Non-participant observation of consultations	TB unit	TB consultations	24 (2 DS patient + 1 DR patient per facility) (Patients who are interviewed)	One year after the intervention start	Researchers	Observation
Non-participant observation of integrated team meetings	Facility	Integrated team meetings	15 (3 per facility in intervention sites only)	1 observation per site at beginning, mid-term, and near end	Researchers	Observation
Local Context Mapping tool	Managers	Conditions for intervention implementation		First two months & One year after the intervention start	Researchers	Face to face interview (IDI guide) + informal observations

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

National	Policy makers	Conditions for	Continuous	Researchers	Face to face
Context		intervention			interview
Mapping tool		implementation			(IDI guide)
					+ informal
					observations
					+ meetings with
					in the CIF team

For peer review only

1.5 Data from the other Results4TB study components

Any realist evaluation starts from the observed outcomes, working backwards to identify the mechanisms, actors and contextual factors that explain them. To achieve this, in addition to the data collected under the RE, we will draw from the data collected by other parts of the trial. For example, data related to effectiveness that we could use could include inpatient & outpatient treatment initiation rates; treatment adherence rate (disaggregated into 'completed' and 'loss to follow-up'); treatment outcome rate (disaggregated into 'cured', 'failure', 'died', and 'not evaluated'); comorbidities rate; rate of referral to other outpatient facilities and rate of hospitalization for management of comorbidities.

Step 4 - Data analysis

RE is method neutral. Data analysis methods should follow the best practices of the disciplines of which it borrows the methods used. In general, the analysis aims to develop Intervention-Context-Actors-Mechanism-Outcome configurations which serve as an analytical heuristic.¹⁴

During the first round of analysis, the following guiding questions will be used: What are the observed outcomes? What is the actual implemented intervention? How was it carried out (duration, intensity, process)? Who delivered the intervention or who are the actors involved? How did the intervention reach the target population and to which degree (coverage)? Can the observed results be linked to the actual intervention?

In a second round of analysis, we will aim to assess the contribution of the actual intervention to the observed outcomes. Guiding questions include: How can the link between the actual intervention and the actual outcomes be explained (mechanisms)? Which context conditions facilitated the policy package to work (or not)? Which conditions constrained the policy? Are there alternative explanations for the observed outcomes (i.e. other interventions or events that may have contributed to the observed outcomes)?

In line with realist principles, a thematic coding approach will be used based on the core elements of the IPT. Framework analysis¹⁵ will be used because it allows for the inclusion of both a priori and emergent concepts. In the first round of analysis data will be categorised using the intervention-actor-context-mechanism-outcome configuration. New interpretations will emerge in subsequent rounds of coding, leading to a refined analysis. This results in descriptions of the actual intervention,

1
2
3
4 its effects (both intended and unintended, positive and negative), the contextual elements and the
5 underlying mechanisms generated in actors.
6
7
8
9
10

11 **Step 5 - Synthesis**

12
13
14 We will use methodological triangulation by combining different qualitative data collection
15 techniques and quantitative analysis, drawing upon data from different sources (interviews,
16 observations, document reviews and the other Results4TB components). The findings of each site
17 will be summarised in reports. Subsequently, a comparison of the facilities will be carried out. The
18 end result will be refined programme theories that specify how the policy played out in different
19 types of contexts and how it affected the outcomes of adherence and loss to follow-up, the
20 endpoints of the trial study.
21
22
23
24
25
26
27

28 **Documentation of the research process**

29
30 The research field team members will write field notes and keep a research diary in the form of a
31 qualitative log, that also tracks the different sources of data collection. Contact summary sheets will
32 be written after each interview or observation to record the researchers' impressions and emerging
33 ideas, and allow new insights to be documented for later retrieval. During the analysis, analytical
34 memos will also be written to allow for an iterative approach. Case analysis meetings will be held
35 regularly in the form of feedback and discussion meetings by the research team. These should allow
36 critical review of observations and preliminary findings and conclusions, as well as peer review.
37
38
39
40
41
42
43

44 **Ethics and Dissemination**

45
46 We will carry out this study according to the principles stated in the Declaration of Helsinki as
47 amended in 2013.¹⁶ Informed consent will be secured from all respondents using information sheets
48 and written informed consent forms, which will be translated to Georgian language. The protocol of
49 Results4TB (including all three components) has been approved by the Institutional Review Board of
50 the National Centre for Disease Control and Public Health in Georgia (Ref. IRB # 2018-019). The
51 realist evaluation component, on which this protocol is based has also been approved by the
52 Institutional Review Board of the Institute of Tropical Medicine, Antwerp (ref IRB #- 1240/18).
53
54
55
56
57
58
59
60

1
2
3
4 Findings will be published in an open-access peer-reviewed journal and further disseminated at
5 international conferences.
6
7
8

9 **Patient and Public Involvement**

10
11 Patients will not be invited to comment on the study design nor to develop patient relevant
12 outcomes or interpret the results. Policy makers, health workers and representatives of the
13 Global Fund were however involved in co-designing the initial program theories during
14 participatory stakeholder workshops. They may be involved in data validation workshops to
15 refine the tested program theories.
16
17
18
19
20
21
22

23 **Discussion**

24
25 This realist evaluation is part of a large theory-driven study that combines a policy trial, cost-
26 effectiveness and realist evaluation studies. The approach offers flexibility and allows iterative
27 reflection while combining different research paradigms. The aim is not to force one paradigm on the
28 other but rather to jointly inform all study components with theoretical insights. This will better
29 integrate data collection and analysis and lead to an integrated assessment of the policy. In this way,
30 the study addresses a hotly debated issue in circles of trials and realist evaluation.¹⁷⁻²⁰ (Van Belle et
31 al., 2016).
32
33
34
35
36
37
38
39

40 **Authors Contributions**

41 BM, ANG and LS conceptualized the study protocol with additional support from IOA and IC. IOA, LS,
42 ANG and BM drafted and finalized the manuscript with contributions from IC. All authors have
43 reviewed and approved the final version of this protocol.
44
45
46
47
48

49 **Acknowledgements**

50
51 We would like to acknowledge the support of other members of the Results4TB study- Maia
52 Uchaneishvili and Natia Shengelia from Curatio International Foundation, Georgia; Sophie Witter and
53 Karin Diaconu from Queen Margaret University, Edinburgh and Anna Vassall from The London School
54 of Hygiene & Tropical Medicine.
55
56
57
58
59
60

Funding Statement

The Results4TB study is a 4-year (2017-2021) project funded under the Health Systems Research Initiative call 3 of the MRC/ESRC/DfID/Wellcome Trust consortium (Grant Ref: MR/P015018/1).

Competing Interests Statement

None declared

REFERENCES

1. World Health Organization. 2017. Tuberculosis Country Profile - Georgia.
2. Curatio International Foundation 2017. Barriers and Facilitators to Adherence to Treatment Among Drug Resistant TB Patients in Georgia. Available on: <https://www.scribd.com/document/340411165/Barriers-and-Facilitators-to-Adherence-to-Tuberculosis-Treatment-Among-Drug-Resistant-TB-Patients-in-Georgia> Accessed: 24-11-2018
3. The Government of Georgia 2015. National Strategic Plan for Tuberculosis Control in Georgia 2016-2020, Ordinance of the Government of Georgia. Available on: <http://tsp.ecom.ngo/files/Tuberculosis-National-Strategic-Plan-2016-2020.pdf> Accessed: 24-11-2018
4. Moore, G., Audrey, S., Barker, M., Bond, L., Bonell, C., Hardeman, W., Moore, L., O'Cathain, A., Tinati, T., Wight, D. & Baird, J. 2015. Process evaluation of complex interventions. UK Medical research Council (MRC) guidance, Medical Research Council.
5. Rycroft-Malone, J., Seers, K., Chandler, J., Hawkes, C., Crichton, N., Allen, C., Bullock, I. & Strunin, L. 2013. The role of evidence, context, and facilitation in an implementation trial: implications for the development of the PARIHS framework. *Implementation Science*, 8.
6. Stern, E., Stame, N., Mayne, J., Forss, K., Davies, R. & Befani, B. 2012. Broadening the range of designs and methods for impact evaluations. London: Department for International Development.
7. Pawson, R. & Tilley, N. 1997. *Realistic Evaluation*, London, Sage.
8. Marchal, B., Van Belle, S., Van Olmen, J., Hoerée, T. & Kegels, G. 2012. Is realist evaluation keeping its promise? A literature review of methodological practice in health systems research. *Evaluation*, 18, 192-212.

- 1
2
3
4 9. Nebot Giralt, A., Nöstlinger, C., Lee, J., Salami, O., Lallemand, M., Onyango-Ouma, W.,
5
6 Nyamongo, I. & Marchal, B. 2017. Understanding the acceptability and adherence to
7
8 paediatric antiretroviral treatment in the new formulation of pellets (LPV/r) – the protocol of
9
10 a realist evaluation. *BMJ Open*, 7.
- 11 10. Renmans, D., Holvoet, N., Garimoi, C. & Criel, B. 2016. Opening the ‘black box’ of
12
13 performance-based financing in low- and lower middle-income countries: a review of the
14
15 literature. *Health Policy and Planning*, 31, 1297-1309.
- 16 11. Rosas, S. 2005. Concept Mapping as a Technique for Program Theory Development: An
17
18 Illustration Using Family Support Programs
- 19 12. Yin, R. 2003. Case study research. Design and methods, London, Sage Publications.
- 20 13. Yin, R. 2009. Case study research. Design and methods, Los Angeles, Sage.
- 21 14. Marchal, B., Kegels, G. & Van Belle, S. 2018. Realist evaluation in health policy and systems
22
23 research: theory incarnate *In: Emmel, N., Greenhalgh, J., ManZANO, A., Monaghan, M. &*
24
25 *Dalkin, S. (eds.) Doing Realist Research. SAGE. London. Sage Publications.*
- 26 15. Ritchie, J., Spencer I. 1994. Qualitative data analysis for applied policy research. *Analyzing*
27
28 *qualitative data. London: Routledge*, pp.173-94.
- 29 16. WMA Declaration of Helsinki – Ethical principles for medical research involving human
30
31 subjects. Available on: [https://www.wma.net/policies-post/wma-declaration-of-helsinki-](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/)
32
33 [ethical-principles-for-medical-research-involving-human-subjects/](https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) Accessed: 24-11-2018
- 34 17. Bonell, C., Fletcher, A., Morton, M., Lorenc, T. & Moore, L. 2012. Realist randomised
35
36 controlled trials: a new approach to evaluating complex public health interventions. *Social*
37
38 *Science and Medicine*, 75, 2299-2306.
- 39 18. Marchal, B., Westhorp, G., Wong, G., Van Belle, S., Greenhalgh, T., Kegels, G. & Pawson, G.
40
41 2013. Realist RCTs of complex interventions - an oxymoron. *Social Science & Medicine*, 94,
42
43 124-128.
- 44 19. Jamal, F., Fletcher, A., Shackleton, N., Elbourne, D., Viner, R. & Bonell, C. 2015. The three
45
46 stages of building and testing mid- level theories in a realist RCT: a theoretical and
47
48 methodological case-example. *Trials*, 466.
- 49 20. Van BELLE, S., Wong, G., Westhorp, G., Pearson, M., Emmel, N., Manzano, A. & Marchal, B.
50
51 2016. Can "realist" randomised controlled trials be genuinely realist? *Trials*, 17, 313.
- 52
53
54
55
56
57
58
59
60





Figure 1. The Realist Cycle

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 **Figure 2. Eliciting the Programme Theory**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41




Figure 3. Initial Programme Theory

BMJ Open

DESIGNING AND EVALUATING PROVIDER RESULTS-BASED FINANCING FOR TUBERCULOSIS CARE IN GEORGIA: A REALIST EVALUATION PROTOCOL

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030257.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Mar-2019
Complete List of Authors:	Marchal, Bruno; Institute of Tropical Medicine, Department of Public Health Giralt , Ariadna; Institute of Tropical Medicine, Department of Public Health Sulaberidze, Lela; Curatio International Foundation Chikovani, Ivdity; Curatio International Foundation Abejirinde, Ibukun-Oluwa; Institute of Tropical Medicine, Department of Public Health
Primary Subject Heading:	Health policy
Secondary Subject Heading:	Health services research, Public health, Global health
Keywords:	realist evaluation, research protocol, Georgia, results-based financing, Health policy < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

DESIGNING AND EVALUATING PROVIDER RESULTS-BASED FINANCING FOR TUBERCULOSIS CARE IN GEORGIA: A REALIST EVALUATION PROTOCOL

Bruno Marchal ¹, Ariadna Nebot Giralt ¹, Lela Sulaberidze ², Ivdity Chikovani ², Ibukun-Oluwa
Omolade Abejirinde* ¹

¹ Institute of Tropical Medicine, Health Systems and Equity Unit, Department of Public
Health, Antwerp, Belgium

² Curatio International Foundation, Tbilisi, Georgia

33
34
35
36
37
38
39
40
41
42
43
44

Corresponding Author

Ibukun-Oluwa Omolade Abejirinde

Institute of Tropical Medicine, Department of Public Health,
Health Systems and Equity Unit,

Nationalestraat 155, Antwerp, Belgium

iabejirinde@itg.be

45
46
47
48
49

Keywords: realist evaluation, research protocol, Georgia, results-based financing, health
policy

50
51
52

Word Count

3804 (including tables)

53
54
55
56
57
58
59
60

Abstract

Introduction

In 2016, Georgian researchers and policymakers were developing a policy to improve the performance of the national tuberculosis (TB) control programme. The research programme “Designing and Evaluating Provider Results-Based Financing for Tuberculosis Care in Georgia: Understanding Costs, Mechanisms of Effect and Impact (Results4TB)” was initiated to inform the policy formulation phase, document the policy implementation and assess the effectiveness, cost-effectiveness and the processes of change. To achieve this, the research team intends to combine an impact evaluation, a cost-effectiveness study and a realist evaluation within an overarching theory-informed design. This protocol is the realist evaluation component of the programme.

Methods

A realist methodological approach will be adopted to guide the research design and evaluation. Realist evaluation answers the question of ‘what works in which conditions for whom?’ and starts with the development of an initial program theory (IPT). The IPT will feed into other phases of the realist research cycle (study design, data collection, data analysis and synthesis, and theory refinement). Data will be collected in a multiple embedded case study design (five intervention and three control sites) through document reviews, in-depth interviews, non-participant observations and context mapping at facility and national levels. Additional data from other research components (cost-effectiveness and impact evaluation) will aid data triangulation.

Ethics and dissemination

The Institutional Review Boards of the National Centre for Disease Control and Public Health in Georgia (ref. IRB # 2018-019) and the Institute of Tropical Medicine, Antwerp (ref. IRB #- 1240/18) have granted ethical approval to the study.

Strengths and Limitations of this study

- This study uses an integrated theory-informed design for a combined impact, cost-effectiveness and process evaluation of a policy, thus addressing a currently debated methodological challenge
- Addressing a policy that is being developed, the study may be faced with unexpected turns in the policymaking and implementation phases.
- The realist evaluation cycle fosters a flexible and iterative structure for learning and reflection. For example, applying a realist approach led to the formulation of a more comprehensive and contextually relevant policy package.

Introduction

Under the national TB program in Georgia, Eastern Europe, Tuberculosis (TB) service is provided to patients free of charge. At outpatient level, services are provided at TB units by TB doctors and TB nurses. There are currently 68 TB units in the country: 58 semi-urban (located in district centers) and 10 urban TB units. Recently, semi-urban TB units were administratively integrated into district and regional level primary health care (PHC) centers, most of which are private. Therefore only a few TB units remain as separate public institutions, existing mainly in the capital and other major cities of the country (10 urban centers). TB service integration into PHC was part of a wider healthcare privatization process whereby although it was not profitable from a private sector perspective, the government (represented by the Ministry of Health through the National TB programme) and private sector providers agreed that the latter will provide TB services. This agreement was scheduled to expire in 2018.

While Georgia has made substantial progress in managing TB, challenges still remain. Data from 2017 indicate high rates of drug-resistant TB (DR-TB) in the Georgian population. The incidence was 11% in new TB patients and 30% in those previously treated.¹ In addition, there is suboptimal adherence to treatment among DR-TB patients in the country - every fourth DR-TB patient quits treatment prematurely. Poor coordination between PHC and TB units leading to fragmented TB care was assumed to contribute to poor treatment adherence and loss to follow-up (LFU).^{2,3}

During discussions on policy options to improve TB service provision in the country, results-based financing (RBF) of providers was proposed as a viable approach to motivate health care providers not only to continue

1
2
3 providing TB care, but also to improve treatment adherence in TB patients. Policymakers' willingness to pilot
4 the RBF model for TB initially materialized as a standard concept note to the Global Fund in 2015, where in
5 addition to other programmatic needs, the government requested financial support from the Global Fund
6 for technical assistance to design and implement the RBF model.
7
8
9

10
11 In 2016, Georgian and international researchers drafted a proposal aiming to support the Georgian
12 government in developing a policy to improve the performance of the National TB control programme and
13 generate evidence on the proposed policy. Consequently, a research programme "Designing and Evaluating
14 Provider Results-Based Financing for Tuberculosis Care in Georgia: Understanding Costs, Mechanisms of
15 Effect and Impact (Results4TB)" was initiated. Results4TB aims at informing the policy formulation phase,
16 documenting the implementation of the policy and assessing the effectiveness, cost-effectiveness and the
17 processes of change. To this end, the research team is combining an impact evaluation of the policy trial
18 with a cost-effectiveness study and a realist evaluation. Essentially, instead of developing three separate
19 sub-studies (impact, cost-effectiveness and process evaluation), each addressing a different set of research
20 questions, we will develop a theory-informed design that integrates all three components. Trial designs
21 often include implementation fidelity evaluations, process evaluations or context mapping,⁴ and there have
22 been calls for informing such evaluations with theory.^{5,6} The Results4TB study therefore goes a step further:
23 not just the process evaluation, but also the overall study design will be theory-informed.
24
25
26
27
28
29
30
31
32
33

34
35 This paper presents the protocol of the realist evaluation component, spelling out the objectives, research
36 questions, methods and ethical considerations. The trial has been registered with ID- ISRCTN14667607
37 (<http://www.isrctn.com/ISRCTN14667607>).
38
39
40
41

42 **Objectives**

43
44

45 The objective of the realist evaluation component is to identify the mechanisms of change and the
46 contextual factors that enhance or undermine the effectiveness of the provider results-based financing
47 policy, defined in terms of adherence and treatment outcomes.
48

49 The research questions include: (1) How is the performance based financing policy designed and by whom?;
50 2) How is the policy implemented in the study sites?; (3) How do the actors respond to the policy?; (4) What
51 are the contextual conditions needed for the policy to work?; (5) What are the underlying mechanisms that
52 explain how the policy contributes to a change in the practice of TB service providers and; (6) What are the
53 underlying mechanisms that explain how the policy contributes to a change in adherence?
54
55
56
57
58
59
60

Methods

The methodological approach

Pawson and Tilley (1997) developed the realist evaluation (RE) approach arguing that in order to be useful for decision makers, rather than merely addressing the question of 'does it work?', evaluations need to answer the question 'what works in which conditions for whom?'.⁷ In order to meet this need, realist evaluators therefore aim to identify the underlying generative mechanisms that explain how an intervention leads to its outcomes and in which context this occurs. Based on critical realism, RE considers that interventions work (or not) because actors respond to what is provided by the intervention (or not). The interaction between 'intervention' and 'actors' in specific 'contexts' therefore triggers mechanisms that lead to outcomes.

Realist evaluations start with an initial programme theory (IPT), on the basis of which the study design is based. The IPT explains how a programme is expected to generate outcomes by showing which mechanisms will be triggered among different groups of actors. It also identifies the necessary contextual conditions needed for the programme, in our case the Results4TB policy, to work. In other words, the IPT is a hypothesis that will be tested subsequently and iteratively through empirical studies. We structured our protocol following the steps of the realist cycle (Figure 1).⁸ The IPT, which has been formulated during stakeholder workshops, is briefly presented, following which additional components of the Results4TB realist evaluation are outlined as part of the research protocol.

Insert Figure 1

Step 1 - Developing the initial programme theory

Several data sources can be used to elicit the initial programme theory (Figure 2). These include programme documents including policy briefs, concept notes and logical frameworks. A second source is interviews with the designers, funders and/or implementers of the policy, combined with on-site observations. Third, past experience, findings of previous evaluations or research studies are reviewed. Finally, in some cases, exploratory research may be carried out.

Insert Figure 2

1
2
3
4
5
6
7 In this project, we combined existing literature reviews, workshops with policymakers and key stakeholders
8 involved in TB care. Furthermore, discussions within the research team were instrumental in refining and
9 constructing the initial programme theory. First, we built upon a review of the literature on adherence
10 carried out in the frame of the RELIVING study⁹ and on literature reviews carried out on performance-based
11 financing (PBF) and results-based financing (RBF), including one on PBF in low- and lower middle-income
12 countries.¹⁰

13
14
15
16 Second, we used the unique opportunity to involve both researchers and policymakers at the initial phase of
17 the project by organising two workshops. During the workshops, we used participatory and interactive
18 techniques to obtain a clearer insight on the proposed RBF policy and why the designers, implementers and
19 other stakeholders think the policy may or may not work. Workshop participants ranged from TB providers
20 to Ministry of Labour, Health and Social Affairs (MoLHSA) policymakers and representatives of the Global
21 Fund. We used cause mapping and concept mapping¹¹ to clarify how the participants understood the
22 problem (first workshop) and the potential policy options, discussing why one option would be more
23 effective than others (second workshop). The results were discussed by the research team members and
24 framed on the background of findings from the literature review.

25
26
27
28
29
30
31
32
33 The result of the above process was that we ended up with a more complex policy; it became evident that
34 the RBF for TB providers required expansion to address other challenges in the service delivery pathway.
35 Consequently, in response to the input from all stakeholders, the policy was defined as a package of
36 interventions, including

- 37 • Incentive payments (bonuses) to TB teams based on performance indicator (i.e. TB patient retained
38 on treatment);
 - 39 • Trainings for all members of a TB team (a TB doctor, a family doctor, a DOT nurse, a rural nurse) on
40 principles of integrated and patient-centred care, and on managing TB treatment side effects and
41 comorbidities (for family doctors and TB doctors);
 - 42 • New roles and responsibilities were ascribed to TB team members which were better aligned to the
43 scope of their professional competencies and in order to ensure integrated patient centred
44 approach for TB
 - 45 • Launch of new treatment and monitoring tools such as: facility managers guidelines on
46 implementing the policy, case management plan for patients, instruments for monitoring integrated
47 team performance, and instruments for verification of performance indicators and the incentive
48 scheme.
- 49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 This process led us to formulate the initial programme theory as follows (Fig. 3):
6

- 7 • Financial incentives will stimulate facility managers to (i) continue providing TB services, (ii) remit
8 incentives to TB providers within their facilities, and (iii) optimise their TB service activities (i.e.
9 *mechanism of organizational self-interest*), on the condition that incentives are considered to be
10 adequate and that sufficient monitoring and regulation systems are in place, in the absence of
11 which gaming and fraud could occur.
- 12 • Provider incentives will increase their extrinsic motivation (*mechanism*) if the staffing and working
13 conditions are adequate. Motivated and competent providers will provide better adherence
14 support to patients, if supervision, monitoring and regulation are adequate. If not, crowding out of
15 intrinsic motivation and gaming may occur.
- 16 • Training for providers (e.g. on side-effect of drugs, management of co-morbidities and patient-
17 centred care) will enhance their competence, which leads to higher self-efficacy. The latter,
18 combined with an increase in extrinsic motivation, contributes to behaviour change; enabling
19 patients to better adhere to the treatment.
- 20 • TB patients who are informed, motivated and supported by providers, and trained to develop the
21 needed skills, will initiate adherence if the social and cultural context is favourable (e.g. no
22 stigma), if the facility is accessible, acceptable and affordable, and if they consider the treatment
23 regime as acceptable.
- 24 • The integration of TB care will improve the continuum of care between general and specialised TB
25 services and thus facilitate the patient to correctly follow the treatment and care pathway
26 towards being cured.
- 27 • TB patients who experience positive effects, feel capable of managing their health condition (i.e.
28 mechanism of self-efficacy) and feel in control are more likely to maintain long-term adherence,
29 on condition that they consider the treatment regime as acceptable.
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Insert Figure 3

The formulated IPT will inform the study design and other phases of the realist cycle.

Step 2 - Study design

Given the research questions, we will adopt the multiple embedded case study design.¹² This design is often used in realist research in health⁸ and has the advantage that it is well adapted to dynamic concepts or interventions, such as a policy that is in the formulation or implementation phase.¹³

We define the case as the uptake and implementation, by facility managers and service providers, of the policy that will be introduced by the Ministry of Labour, Health and Social Affairs to improve TB drug adherence and treatment outcomes. The unit of analysis is the facility, which includes first-line and second-line health facilities in which TB care is provided. Within each facility, we focus on the influence of the policy on the interaction between managers, service providers and patients, and on TB service delivery. In realist evaluation, the selection of the study sites is purposive: ideally, sites should enable 'testing' of the initial programme theory in all its dimensions. The trial of the policy will be implemented in eight intervention and eight control facilities. For the realist evaluation, five intervention sites and three control sites will be chosen for data collection. Site selection will be purposive, based on the following criteria:

- Facilities of different types will be selected using ownership status (private-for-profit versus public) and organizational structure (large chain versus independent facility)
- Different subsets of service delivery modality- specialized TB services versus TB units integrated in primary health care centres.
- Location- semi-urban versus urban

Step 3 - Data collection

We will use a range of data collection techniques: document reviews, in-depth interviews, non-participant observations and a context mapping tool (Table 1). Additional data from other components of Results4TB will also be used to triangulate the data. Where possible data collection tools will be tested during a short pilot phase of the policy prior to full trial.

1.1 Document review

We will carry out a document review to collect data for research question 2 (i.e. how the policy is implemented in the study sites). The focus will be on finding evidence of the initiation and process of policy implementation at the facility. Facility reports, TB programme reports, data collected during policy implementation supervision and verification reports, and other relevant policy-related documents will be used. At study sites, documents related to monitoring of TB clinic activities, such as activity reports, will be

1
2
3 screened for information on implementation process and problems. Where possible, electronic versions will
4 be collected and entered in NVIVO software. If not, paper versions will be collected.
5
6

7 **1.2 In-depth interviews**

8
9 In order to address research questions 3- 6, we will carry out in-depth interviews with different actors in the
10 policy trail: facility managers, TB service providers, TB coordinators (who will conduct policy supervision and
11 verification role), TB patients and national-level respondents. Interview guides will be developed in
12 collaboration with the other project teams and with the local partner in Georgia. The guides will be first
13 translated into Georgian, piloted, and modified if needed. Table 1 presents the estimated number of
14 interviews per respondent type and level.
15
16
17
18

19 The following procedure will be used:

- 20
21 • All potential respondents will be invited to participate in the study by personal invitation using a
22 snowball approach. The researchers will invite facility managers, health care personnel and
23 national-level respondents. TB doctors will extend invitations to their patients, after receiving
24 training from the research team on recruitment and ethical procedures.
25
26
27
- 28 • Interested potential respondents will then receive and be guided through a participant
29 information sheet, explaining the study objectives and procedures.
30
31
- 32 • If participants are still interested to be interviewed, an interview will be arranged according to
33 their preferred time and location.
34
35
- 36 • At the start of the interview, the researchers will provide detailed information about the study
37 and the interview and answer any question.
38
39
- 40 • The informed consent form will be presented and explained by the researcher. Informed consent
41 will be sought at the start of the interview, as well as permission to record the interview.
42
43
- 44 • All recorded transcripts will be transcribed verbatim. A sample of interviews will be translated to
45 be used in an initial coding training workshop and will also allow for quality assessment by the
46 non-Georgian team members.
47
48
- 49 • Field-notes and memos will be entered in an electronic form.
50
51
- 52 • All transcripts and related memos will be entered in NVIVO for subsequent data analysis.
53

54 **1.3 Non-participant observation**

55 To collect information related to research questions 2 - 6, in addition to individual interviews, we will
56 conduct non-participant observations at TB clinics and observe the integrated TB team meetings, using
57 observation guides. Where possible, we will aim to observe the clinical encounter of each patient who has
58 agreed to be interviewed. Researchers will ask for written informed consent before conducting any
59 observation. Patients will be able to opt out, yet still participate in an interview.
60

1.4 Context mapping tool

In order to document the context of each facility and to identify contextual conditions for the intervention to work (research question 3), we will develop and use a facility context-mapping tool. This will be used to document key facility-related issues, including organisational structure, decision spaces, flow of funds and information, and the TB patient pathway. A national context mapping tool will be developed and used to identify the key stakeholders, track their engagement with the policy over time, identify key political and policy events and other events that may influence the policy implementation and or its outcomes.

For peer review only

Table 1 - Overview of data collection methods and targeted minimum numbers

Tools	Data source	Content	Minimum numbers	Time period	Responsible for data collection	Data collection technique
IDI-Providers	Service providers: TB doctor, TB nurse, family doctor, rural doctor, rural nurse	Personnel perspectives	40 (5 interviews/site)	One year after the intervention start	Researchers	Face to face interview (IDI guides)
IDI-Facility Managers	Facility manager, clinical manager	Managers perspectives	16 (2 interviews/site)	One year after the intervention start	Researchers	Face to face interview (IDI guides)
IDI-TB Coordinator	TB Coordinator	TB coordinators views	5	One year after the intervention start	Researchers	Face to face interview (IDI guides)
IDI-Patients	Patient	Patients perspectives	48 (3 DS + 3 DR patients per site)	One year after the intervention start	Researchers	Face to face interview (IDI guides)
IDI-National level	MoLHSA, National Center for Disease Control	National-level key actors' perspectives	5 interviews	15 months after the intervention start	Researchers	Face to face interview

respondents	(NCDC), the Global Fund, TB programme, Social Service Agency (SSA)					(IDI guides)
IDI-Network HQ	Top managers from each network	Network specific views	3 Interviews	One year after the intervention start	Researchers	Face to face interview (IDI guides)
Non-participant observation of consultations	TB unit	TB consultations	24 (2 DS patient + 1 DR patient per facility) (Patients who are interviewed)	One year after the intervention start	Researchers	Observation
Non-participant observation of integrated team meetings	Facility	Integrated team meetings	15 (3 per facility in intervention sites only)	1 observation per site at beginning, mid-term, and near end	Researchers	Observation
Local Context Mapping tool	Managers	Conditions for intervention implementation		First two months & One year after the intervention start	Researchers	Face to face interview (IDI guide) + informal observations

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

National	Policy makers	Conditions for	Continuous	Researchers	Face to face
Context		intervention			interview
Mapping tool		implementation			(IDI guide)
					+ informal
					observations
					+ meetings with
					in the CIF team

For peer review only

1.5 Data from the other Results4TB study components

Any realist evaluation starts from the observed outcomes, working backwards to identify the mechanisms, actors and contextual factors that explain them. To achieve this, in addition to the data collected under the RE, we will draw from the data collected by other parts of the trial. For example, data related to effectiveness that we could use could include inpatient & outpatient treatment initiation rates; treatment adherence rate (disaggregated into 'completed' and 'loss to follow-up'); treatment outcome rate (disaggregated into 'cured', 'failure', 'died', and 'not evaluated'); comorbidities rate; rate of referral to other outpatient facilities and rate of hospitalization for management of comorbidities.

Step 4 - Data analysis

RE is method neutral. Data analysis methods should follow the best practices of the disciplines of which it borrows the methods used. In general, the analysis aims to develop Intervention-Context-Actors-Mechanism-Outcome configurations which serve as an analytical heuristic.¹⁴

During the first round of analysis, the following guiding questions will be used: What are the observed outcomes? What is the actual implemented intervention? How was it carried out (duration, intensity, process)? Who delivered the intervention or who are the actors involved? How did the intervention reach the target population and to which degree (coverage)? Can the observed results be linked to the actual intervention?

In a second round of analysis, we will aim to assess the contribution of the actual intervention to the observed outcomes. Guiding questions include: How can the link between the actual intervention and the actual outcomes be explained (mechanisms)? Which context conditions facilitated the policy package to work (or not)? Which conditions constrained the policy? Are there alternative explanations for the observed outcomes (i.e. other interventions or events that may have contributed to the observed outcomes)?

In line with realist principles, a thematic coding approach will be used based on the core elements of the IPT. Framework analysis¹⁵ will be used because it allows for the inclusion of both a priori and emergent concepts. In the first round of analysis data will be categorised using the intervention-actor-context-mechanism-outcome configuration. New interpretations will emerge in subsequent rounds of coding, leading to a refined analysis. This results in descriptions of the actual intervention,

1
2
3
4 its effects (both intended and unintended, positive and negative), the contextual elements and the
5 underlying mechanisms generated in actors.
6
7
8
9
10

11 **Step 5 - Synthesis**

12
13
14 We will use methodological triangulation by combining different qualitative data collection
15 techniques and quantitative analysis, drawing upon data from different sources (interviews,
16 observations, document reviews and the other Results4TB components). The findings of each site
17 will be summarised in reports. Subsequently, a comparison of the facilities will be carried out. The
18 end result will be refined programme theories that specify how the policy played out in different
19 types of contexts and how it affected the outcomes of adherence and loss to follow-up, the
20 endpoints of the trial study.
21
22
23
24
25
26
27

28 **Documentation of the research process**

29
30 The research field team members will write field notes and keep a research diary in the form of a
31 qualitative log, that also tracks the different sources of data collection. Contact summary sheets will
32 be written after each interview or observation to record the researchers' impressions and emerging
33 ideas, and allow new insights to be documented for later retrieval. During the analysis, analytical
34 memos will also be written to allow for an iterative approach. Case analysis meetings will be held
35 regularly in the form of feedback and discussion meetings by the research team. These should allow
36 critical review of observations and preliminary findings and conclusions, as well as peer review.
37
38
39
40
41
42
43

44 **Ethics and Dissemination**

45
46 We will carry out this study according to the principles stated in the Declaration of Helsinki as
47 amended in 2013.¹⁶ Informed consent will be secured from all respondents using information sheets
48 and written informed consent forms, which will be translated to Georgian language. The protocol of
49 Results4TB (including all three components) has been approved by the Institutional Review Board of
50 the National Centre for Disease Control and Public Health in Georgia (Ref. IRB # 2018-019). The
51 realist evaluation component, on which this protocol is based has also been approved by the
52 Institutional Review Board of the Institute of Tropical Medicine, Antwerp (ref IRB #- 1240/18).
53
54
55
56
57
58
59
60

1
2
3
4 Findings will be published in an open-access peer-reviewed journal and further disseminated at
5 international conferences.
6
7
8

9 **Patient and Public Involvement**

10
11 Patients will not be invited to comment on the study design nor to develop patient relevant
12 outcomes or interpret the results. Policy makers, health workers and representatives of the
13 Global Fund were however involved in co-designing the initial program theories during
14 participatory stakeholder workshops. They may be involved in data validation workshops to
15 refine the tested program theories.
16
17
18
19
20
21
22

23 **Discussion**

24
25 This realist evaluation is part of a large theory-driven study that combines a policy trial, cost-
26 effectiveness and realist evaluation studies. The approach offers flexibility and allows iterative
27 reflection while combining different research paradigms. The aim is not to force one paradigm on the
28 other but rather to jointly inform all study components with theoretical insights. This will better
29 integrate data collection and analysis and lead to an integrated assessment of the policy. In this way,
30 the study addresses a hotly debated issue in circles of trials and realist evaluation.¹⁷⁻²⁰
31
32
33
34
35
36
37

38 **Authors Contributions**

39
40 BM, ANG and LS conceptualized the study protocol with additional support from IOA and IC. IOA, LS,
41 ANG and BM drafted and finalized the manuscript with contributions from IC. All authors have
42 reviewed and approved the final version of this protocol.
43
44
45
46

47 **Acknowledgements**

48
49 We would like to acknowledge the support of other members of the Results4TB study- Maia
50 Uchaneishvili and Natia Shengelia from Curatio International Foundation, Georgia; Sophie Witter and
51 Karin Diaconu from Queen Margaret University, Edinburgh and Anna Vassall from The London School
52 of Hygiene & Tropical Medicine.
53
54
55
56
57
58
59
60

Funding Statement

The Results4TB study is a 4-year (2017-2021) project funded under the Health Systems Research Initiative call 3 of the MRC/ESRC/DfID/Wellcome Trust consortium (Grant Ref: MR/P015018/1).

Competing Interests Statement

None declared

Figure Legends

Figure 1- The realist cycle

Figure 2- Eliciting the programme theory

Figure 3- Initial programme theory

REFERENCES

1. World Health Organization. 2017. Tuberculosis Country Profile - Georgia.
2. Curatio International Foundation 2017. Barriers and Facilitators to Adherence to Treatment Among Drug Resistant TB Patients in Georgia. Available on: <https://www.scribd.com/document/340411165/Barriers-and-Facilitators-to-Adherence-to-Tuberculosis-Treatment-Among-Drug-Resistant-TB-Patients-in-Georgia> Accessed: 24-11-2018
3. The Government of Georgia 2015. National Strategic Plan for Tuberculosis Control in Georgia 2016-2020, Ordinance of the Government of Georgia. Available on: <http://tsp.ecom.ngo/files/Tuberculosis-National-Strategic-Plan-2016-2020.pdf> Accessed: 24-11-2018
4. Moore, G., Audrey, S., Barker, M., Bond, L., Bonell, C., Hardeman, W., Moore, L., O'Cathain, A., Tinati, T., Wight, D. & Baird, J. 2015. Process evaluation of complex interventions. UK Medical research Council (MRC) guidance, Medical Research Council.
5. Rycroft-Malone, J., Seers, K., Chandler, J., Hawkes, C., Crichton, N., Allen, C., Bullock, I. & Strunin, L. 2013. The role of evidence, context, and facilitation in an implementation trial: implications for the development of the PARIHS framework. *Implementation Science*, 8.
6. Stern, E., Stame, N., Mayne, J., Forss, K., Davies, R. & Befani, B. 2012. Broadening the range of designs and methods for impact evaluations. London: Department for International Development.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
7. Pawson, R. & Tilley, N. 1997. *Realistic Evaluation*, London, Sage.
8. Marchal, B., Van Belle, S., Van Olmen, J., Hoerée, T. & Kegels, G. 2012. Is realist evaluation keeping its promise? A literature review of methodological practice in health systems research. *Evaluation*, 18, 192-212.
9. Nebot Giral, A., Nöstlinger, C., Lee, J., Salami, O., Lallemand, M., Onyango-Ouma, W., Nyamongo, I. & Marchal, B. 2017. Understanding the acceptability and adherence to paediatric antiretroviral treatment in the new formulation of pellets (LPV/r) – the protocol of a realist evaluation. *BMJ Open*, 7.
10. Renmans, D., Holvoet, N., Garimoi, C. & Criel, B. 2016. Opening the ‘black box’ of performance-based financing in low- and lower middle-income countries: a review of the literature. *Health Policy and Planning*, 31, 1297-1309.
11. Rosas, S. 2005. Concept Mapping as a Technique for Program Theory Development: An Illustration Using Family Support Programs
12. Yin, R. 2003. Case study research. Design and methods, London, Sage Publications.
13. Yin, R. 2009. Case study research. Design and methods, Los Angeles, Sage.
14. Marchal, B., Kegels, G. & Van Belle, S. 2018. Realist evaluation in health policy and systems research: theory incarnate *In: Emmel, N., Greenhalgh, J., ManZANO, A., Monaghan, M. & Dalkin, S. (eds.) Doing Realist Research. SAGE. London. Sage Publications.*
15. Ritchie, J., Spencer I. 1994. Qualitative data analysis for applied policy research. *Analyzing qualitative data. London: Routledge*, pp.173-94.
16. WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. Available on: <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/> Accessed: 24-11-2018
17. Bonell, C., Fletcher, A., Morton, M., Lorenc, T. & Moore, L. 2012. Realist randomised controlled trials: a new approach to evaluating complex public health interventions. *Social Science and Medicine*, 75, 2299-2306.
18. Marchal, B., Westhorp, G., Wong, G., Van Belle, S., Greenhalgh, T., Kegels, G. & Pawson, G. 2013. Realist RCTs of complex interventions - an oxymoron. *Social Science & Medicine*, 94, 124-128.
19. Jamal, F., Fletcher, A., Shackleton, N., Elbourne, D., Viner, R. & Bonell, C. 2015. The three stages of building and testing mid- level theories in a realist RCT: a theoretical and methodological case-example. *Trials*, 466.

1
2
3
4 20. Van BELLE, S., Wong, G., Westhorp, G., Pearson, M., Emmel, N., Manzano, A. & Marchal, B.
5
6 2016. Can "realist" randomised controlled trials be genuinely realist? *Trials*, 17, 313.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. The Realist Cycle

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41




Figure 2. Eliciting the Programme Theory

Facility managers

BMJ Open

Incentives for organisation

Adequate control and regulation

Negative effects:
Gaming, fraud

Renumeration
of TB providers

Staffing

Working
conditions

Training

Integration

Providers

Provider's competences

Provider motivation
(intrinsic - extrinsic)

Incentives for providers

Adequate supervision, control
and regulation

Negative effects:
Crowding out of intrinsic motivation, fraud

Facility-related factors
Geographical access to facilities
Acceptability of care
Affordability of care

Provider practices

Cultural and social factors
Stigma
Support

Patient-related factors
Patient motivation
Information
Health beliefs

Incentives for patients

Treatment regimen

Patient-related factors
Self-efficacy
Control
Experience of results

Patients

Diagnosis of TB

Patient's decision

Initiation of treatment

Implementation or long-term adherence

Treatment outcome

Non-initiation

Discontinuation

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Figure 3. Initial Programme Theory

